Roundtable: UC at UEGW 2023

Making sense of new treatments and data

Experts discuss the latest on ulcerative colitis (UC) from the 2023 United European Gastroenterology Week. Click to go straight to:

• Do guidelines matter?
• Drug safety: Updates and communicating with patients
• Integrating new treatments into practice
• Questions: Data highlights and best practice

Do guidelines matter when new treatments overtake every update? Dr Marla Dubinsky leads this discussion on the place of international and local UC guidelines in daily decision-making.

What key safety data for UC medications were reported at UEGW 2023? Dr Tim Raine leads this discussion, which includes how to discuss drug safety profiles with patients.

How can healthcare professionals shift old prescribing habits and integrate novel UC treatments into routine care? Dr Alissa Walsh leads the discussion.

Dr Raine puts questions to Dr Walsh and Dr Dubinsky, including their UEGW 2023 takeaways, key upcoming trials and the one practice change they advocate to help people with UC.

Resources

ECCO guidelines on UC management
ACG guidelines on UC management
AGA guidelines on UC management
The VARSITY trial: Vedolizumab versus adalimumab
Mirikizumab and bowel urgency (analysis of two phase 3 trials)

Meet the experts

Dr Tim Raine

Dr Tim Raine leads the inflammatory bowel disease (IBD) clinical service and the IBD trials unit at Cambridge University Hospitals, UK. Dr Raine is the chair of the European Crohn’s and Colitis Organisation (ECCO) guidelines committee and is a lead author on several ECCO guidelines. His research focuses on the regulation of the gastrointestinal immune system, and is funded by the Wellcome Trust, CCFA, Crohn’s and Colitis UK, OpenTargets and the National Institute for Health Research.

Disclosures

Dr Raine has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Roche, Sandoz, Takeda, UCB, and Xap therapeutics.

Dr Marla Dubinsky

 Marla C Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, USA, and the Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai. She is the co-founder of Cornerstones Health, which is a non-profit organisation dedicated to enhancing and transforming communication between healthcare providers, patients and industry partners through creative, comprehensive and expert-based educational programmes. Professor Dubinsky is also the co-founder of Trellus Health, a resilience driven connected health solution for chronic conditions, leading with IBD. Her research interests focus on personalised medicine in IBD and predictors of rapid disease progression with the goal of preventing complications by altering treatment plans. She is also the co-founder of WECARE in IBD, an organisation dedicated to the health of women with IBD.

Disclosures

Consultant and advisor for AbbVie, Abivax, AstraZeneca, Bristol Myers Squib, Gilead, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, and Takeda.

Dr Alissa Walsh

Alissa Walsh is the Clinical Director of Gastroenterology and Endoscopy and a Consultant Gastroenterologist at the John Radcliffe Hospital in Oxford, UK.

Her research interests include IBD activity indices, prevention of opportunistic infections in immunocompromised patients, the role of faecal transplantation in ulcerative colitis and remote monitoring for people with IBD. Dr Walsh is a founder and director of Crohn’s Colitis Cure, an Australian charity supporting IBD medical research.

Disclosures

Consultation/speaker fees and/or research support from AbbVie, Buhlmann, Falk, Ferring, Galapagos, Helmsley Trust, Janssen, Lilly, Norman Collinson Foundation, Pfizer, Shire, Takeda, Tillotts Pharma, and Vifor.